{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:22:56Z","timestamp":1787066576246,"version":"build-2736575974"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) provides a revised classification of lymphoid malignancies including chronic lymphocytic leukemia (CLL) and plasma cell myeloma\/multiple myeloma (PCM\/MM). For both diseases the descriptions of precursor states such as monoclonal B-cell lymphocytosis and monoclonal gammopathy of uncertain significance (MGUS) have been updated including a better risk stratification model. New insights on mutational landscapes and branching evolutionary pattern were embedded as diagnostic and prognostic factors, accompanied by a revised structure for the chapter of plasma cell neoplasms. Thus, the WHO-HAEM5 leads to practical improvements of biological and clinical relevance for pathologists, clinicians, geneticists and scientists in the field of lymphoid malignancies. The present review gives an overview on the landscape of genetic alterations in CLL and plasma cell neoplasms with a focus on their impact on classification and treatment.<\/jats:p>","DOI":"10.1515\/medgen-2024-2006","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T02:43:33Z","timestamp":1709693013000},"page":"47-57","source":"Crossref","is-referenced-by-count":4,"title":["Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms\u00a0\u2013 a practical guide to WHO HAEM5"],"prefix":"10.1515","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-1226","authenticated-orcid":false,"suffix":"1","given":"Eugen","family":"Tausch","sequence":"first","affiliation":[{"name":"Ulm University Division of CLL, Department of Internal Medicine 3 Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-1659","authenticated-orcid":false,"suffix":"PhD 2,3,4","given":"Cristina","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Phi i Sunyer (IDIBAPS) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-9296","authenticated-orcid":false,"suffix":"1","given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Ulm University, Division of CLL, Department of Internal Medicine 3 Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-5323","authenticated-orcid":false,"suffix":"5","given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[{"name":"Ulm University and Ulm University Medical Center Institute of Human Genetics Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2024080804524290214_j_medgen-2024-2006_ref_001","doi-asserted-by":"crossref","unstructured":"Alaggio, Rita, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, et al. (2022): The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7). 1720\u20131748. doi:10.1038\/s41375-022-01620-2.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_002","doi-asserted-by":"crossref","unstructured":"Al-Sawaf, Othman, Can Zhang, Tong Lu, Michael Z. Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, et al. (2021): Minimal Residual Disease Dynamics after venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of Clinical Oncology. Wolters Kluwer. 39(36). 4049\u20134060. doi:10.1200\/JCO.21.01181.","DOI":"10.1200\/JCO.21.01181"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_003","doi-asserted-by":"crossref","unstructured":"Baliakas, Panagiotis, Sabine Jeromin, Michalis Iskas, Anna Puiggros, Karla Plevova, Florence Nguyen-Khac, Zadie Davis, et al. (2019): Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 133(11). 1205\u20131216. doi:10.1182\/blood-2018-09-873083.","DOI":"10.1182\/blood-2018-09-873083"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_004","doi-asserted-by":"crossref","unstructured":"Blombery, Piers, Mary Ann Anderson, Jia-Nan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, et al. (2019): Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery 9(3). 342\u2013353. doi:10.1158\/2159-8290.CD-18-1119.","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_005","doi-asserted-by":"crossref","unstructured":"Boyle, Eileen M., Shayu Deshpande, Ruslana Tytarenko, Cody Ashby, Yan Wang, Michael A. Bauer, Sarah K. Johnson, et al. (2021): The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications 12(1). 293. doi:10.1038\/s41467-020-20524-2.","DOI":"10.1038\/s41467-020-20524-2"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_006","doi-asserted-by":"crossref","unstructured":"Bros\u00e9us, Julien, S\u00e9bastien Hergalant, Julia Vogt, Eugen Tausch, Markus Kreuz, Anja Mottok, Christof Schneider, et al. (2023): Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nature Communications 14(1). 309. doi:10.1038\/s41467-022-34642-6.","DOI":"10.1038\/s41467-022-34642-6"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_007","doi-asserted-by":"crossref","unstructured":"Brown, J. R., P. Hillmen, S. O\u2019Brien, J. C. Barrientos, N. M. Reddy, S. E. Coutre, C. S. Tam, et al. (2017): Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL. Leukemia doi:10.1038\/leu.2017.175.","DOI":"10.1038\/leu.2017.175"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_008","doi-asserted-by":"crossref","unstructured":"Bustoros, Mark, Romanos Sklavenitis-Pistofidis, Jihye Park, Robert Redd, Benny Zhitomirsky, Andrew J. Dunford, Karma Salem, et al. (2020): Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology. Wolters Kluwer. 38(21). 2380\u20132389. doi:10.1200\/JCO.20.00437.","DOI":"10.1200\/JCO.20.00437"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_009","doi-asserted-by":"crossref","unstructured":"Condoluci, Adalgisa, Lodovico Terzi di Bergamo, Petra Langerbeins, Manuela A. Hoechstetter, Carmen D. Herling, Lorenzo De Paoli, Julio Delgado, et al. (2020): International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135(21). 1859\u20131869. doi:10.1182\/blood.2019003453.","DOI":"10.1182\/blood.2019003453"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_010","doi-asserted-by":"crossref","unstructured":"D\u00f6hner, Hartmut, Stephan Stilgenbauer, Axel Benner, Elke Leupolt, Alexander Kr\u00f6ber, Lars Bullinger, Konstanze D\u00f6hner, Martin Bentz & Peter Lichter (2000): Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. New England Journal of Medicine 343(26). 1910\u20131916. doi:10.1056\/NEJM200012283432602.","DOI":"10.1056\/NEJM200012283432602"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_011","doi-asserted-by":"crossref","unstructured":"Fazi, Claudia, Lydia Scarf\u00f2, Lorenza Pecciarini, Francesca Cottini, Antonis Dagklis, Agnieszka Janus, Anna Talarico, et al. (2011): General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 118(25). 6618\u20136625. doi:10.1182\/blood-2011-05-357251.","DOI":"10.1182\/blood-2011-05-357251"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_012","doi-asserted-by":"crossref","unstructured":"F\u00fcrstenau, Moritz, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, et al. (2023): High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood 142(5). 446\u2013459. doi:10.1182\/blood.2023019634.","DOI":"10.1182\/blood.2023019634"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_013","doi-asserted-by":"crossref","unstructured":"Hallek, Michael, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut D\u00f6hner, Peter Hillmen, et al. (2018): iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25). 2745\u20132760. doi:10.1182\/blood-2017-09-806398.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_014","doi-asserted-by":"crossref","unstructured":"Hamblin, T. J., Z. Davis, A. Gardiner, D. G. Oscier & F. K. Stevenson (1999): Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6). 1848\u20131854.","DOI":"10.1182\/blood.V94.6.1848.418k05_1848_1854"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_015","doi-asserted-by":"crossref","unstructured":"International CLL-IPI working group (2016): An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. The Lancet. Oncology 17(6). 779\u2013790. doi:10.1016\/S1470-2045(16)30029-8.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_016","doi-asserted-by":"crossref","unstructured":"Jaramillo, Sonia, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, et al. (2020): Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica 105(11). 2598\u20132607. doi:10.3324\/haematol.2019.231027.","DOI":"10.3324\/haematol.2019.231027"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_017","doi-asserted-by":"crossref","unstructured":"Knisbacher, Binyamin A., Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Mart\u00ed Duran-Ferrer, Kristen E. Stevenson, Eugen Tausch, et al. (2022): Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nature Genetics. Nature Publishing Group. 54(11). 1664\u20131674. doi:10.1038\/s41588-022-01140-w.","DOI":"10.1038\/s41588-022-01140-w"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_018","doi-asserted-by":"crossref","unstructured":"Langerbeins, Petra, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz F\u00fcrstenau, Othman Al-Sawaf, Julia von Tresckow, et al. (2022): The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia. Blood 139(2). 177\u2013187. doi:10.1182\/blood.2021010845.","DOI":"10.1182\/blood.2021010845"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_019","doi-asserted-by":"crossref","unstructured":"Ma\u0142ecka, Agnieszka, Gunhild Tr\u00f8en, Anne Tierens, Ingunn \u00d8stlie, J\u0119drzej Ma\u0142ecki, Ulla Randen, Junbai Wang, Sigbj\u00f8rn Berentsen, Geir E. Tj\u00f8nnfjord & Jan M. A. Delabie (2018): Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. British Journal of Haematology 183(5). 838\u2013842. doi:10.1111\/bjh.15063.","DOI":"10.1111\/bjh.15063"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_020","doi-asserted-by":"crossref","unstructured":"Maura, Francesco, Niccol\u00f3 Bolli, Nicos Angelopoulos, Kevin J. Dawson, Daniel Leongamornlert, Inigo Martincorena, Thomas J. Mitchell, et al. (2019): Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nature Communications. Nature Publishing Group. 10(1). 3835. doi:10.1038\/s41467-019-11680-1.","DOI":"10.1038\/s41467-019-11680-1"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_021","doi-asserted-by":"crossref","unstructured":"Parry, Erin M., Ignaty Leshchiner, Romain Gui\u00e8ze, Connor Johnson, Eugen Tausch, Sameer A. Parikh, Camilla Lemvigh, et al. (2023): Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nature Medicine 29(1). 158\u2013169. doi:10.1038\/s41591-022-02113-6.","DOI":"10.1038\/s41591-022-02113-6"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_022","doi-asserted-by":"crossref","unstructured":"Rajkumar, S. Vincent, Robert A. Kyle, Terry M. Therneau, L. Joseph Melton, Arthur R. Bradwell, Raynell J. Clark, Dirk R. Larson, Matthew F. Plevak, Angela Dispenzieri & Jerry A. Katzmann (2005): Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106(3). 812\u2013817. doi:10.1182\/blood-2005-03-1038.","DOI":"10.1182\/blood-2005-03-1038"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_023","doi-asserted-by":"crossref","unstructured":"Ramos-Campoy, Silvia, Anna Puiggros, S\u00edlvia Be\u00e0, Sandrine Bougeon, Mar\u00eda Jos\u00e9 Larr\u00e1yoz, Dolors Costa, Helen Parker, et al. (2022): Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. Haematologica 107(3). 593\u2013603. doi:10.3324\/haematol.2020.274456.","DOI":"10.3324\/haematol.2020.274456"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_024","doi-asserted-by":"crossref","unstructured":"Rawstron, Andy C., Karl-Anton Kreuzer, Asha Soosapilla, Martin Spacek, Olga Stehlikova, Peter Gambell, Neil McIver-Brown, et al. (2018): Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry. Part B, Clinical Cytometry 94(1). 121\u2013128. doi:10.1002\/cyto.b.21595.","DOI":"10.1002\/cyto.b.21595"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_025","doi-asserted-by":"crossref","unstructured":"Robbe, Pauline, Kate E. Ridout, Dimitrios V. Vavoulis, Helene Dr\u00e9au, Ben Kinnersley, Nicholas Denny, Daniel Chubb, et al. (2022): Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. Nature Genetics 54(11). 1675\u20131689. doi:10.1038\/s41588-022-01211-y.","DOI":"10.1038\/s41588-022-01211-y"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_026","doi-asserted-by":"crossref","unstructured":"Rosenquist, R., P. Ghia, A. Hadzidimitriou, L.-A. Sutton, A. Agathangelidis, P. Baliakas, N. Darzentas, et al. (2017): Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia 31(7). 1477\u20131481. doi:10.1038\/leu.2017.125.","DOI":"10.1038\/leu.2017.125"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_027","doi-asserted-by":"crossref","unstructured":"Shanafelt, T. D., P. Ghia, M. C. Lanasa, O. Landgren & A. C. Rawstron (2010): Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 24(3). 512\u2013520. doi:10.1038\/leu.2009.287.","DOI":"10.1038\/leu.2009.287"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_028","doi-asserted-by":"crossref","unstructured":"Stilgenbauer, Stephan, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze D\u00f6hner, Andreas B\u00fchler, et al. (2014a): Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123(21). 3247\u20133254. doi:10.1182\/blood-2014-01-546150.","DOI":"10.1182\/blood-2014-01-546150"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_029","doi-asserted-by":"crossref","unstructured":"Tausch, Eugen, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, et al. (2020): Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. American Society of Hematology. 135(26). 2402\u20132412. doi:10.1182\/blood.2019004492.","DOI":"10.1182\/blood.2019004492"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_030","doi-asserted-by":"crossref","unstructured":"Woyach, Jennifer A., Richard R. Furman, Ta-Ming Liu, Hatice Gulcin Ozer, Marc Zapatka, Amy S. Ruppert, Ling Xue, et al. (2014): Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. The New England Journal of Medicine 370(24). 2286\u20132294. doi:10.1056\/NEJMoa1400029.","DOI":"10.1056\/NEJMoa1400029"},{"key":"2024080804524290214_j_medgen-2024-2006_ref_031","doi-asserted-by":"crossref","unstructured":"Zenz, Thorsten, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja H\u00e4be, Dirk Winkler, Andreas B\u00fchler, et al. (2010): TP53 mutation and survival in chronic lymphocytic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28(29). 4473\u20134479. doi:10.1200\/JCO.2009.27.8762.","DOI":"10.1200\/JCO.2009.27.8762"}],"container-title":["Medizinische Genetik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/medgen-2024-2006\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/medgen-2024-2006\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:54:45Z","timestamp":1723078485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/medgen-2024-2006\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,6]]},"published-print":{"date-parts":[[2024,3,4]]}},"alternative-id":["10.1515\/medgen-2024-2006"],"URL":"https:\/\/doi.org\/10.1515\/medgen-2024-2006","relation":{},"ISSN":["1863-5490","0936-5931"],"issn-type":[{"value":"1863-5490","type":"electronic"},{"value":"0936-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}